ERRB2 (formerly HER2)-positive advanced breast cancer (ABC) remains typically incurable with optimal treatment undefined in later lines of therapy. The chimeric antibody margetuximab shares ERBB2 specificity with trastuzumab but incorporates an engineered Fc region to increase immune activation.
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial / Rugo, Hope S; Im, Seock-Ah; Cardoso, Fatima; Cortés, Javier; Curigliano, Giuseppe; Musolino, Antonino; Pegram, Mark D; Wright, Gail S; Saura, Cristina; Escrivá-de-Romaní, Santiago; De Laurentiis, Michelino; Levy, Christelle; Brown-Glaberman, Ursa; Ferrero, Jean-Marc; de Boer, Maaike; Kim, Sung-Bae; Petráková, Katarína; Yardley, Denise A; Freedman, Orit; Jakobsen, Erik H; Kaufman, Bella; Yerushalmi, Rinat; Fasching, Peter A; Nordstrom, Jeffrey L; Bonvini, Ezio; Koenig, Scott; Edlich, Sutton; Hong, Shengyan; Rock, Edwin P; Gradishar, William J. - In: JAMA ONCOLOGY. - ISSN 2374-2437. - (2021). [10.1001/jamaoncol.2020.7932]
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial
Musolino, Antonino;
2021-01-01
Abstract
ERRB2 (formerly HER2)-positive advanced breast cancer (ABC) remains typically incurable with optimal treatment undefined in later lines of therapy. The chimeric antibody margetuximab shares ERBB2 specificity with trastuzumab but incorporates an engineered Fc region to increase immune activation.| File | Dimensione | Formato | |
|---|---|---|---|
|
jamaoncology_rugo_2021_oi_200114_1611083625.00813 (1).pdf
accesso aperto
Tipologia:
Versione (PDF) editoriale
Licenza:
Creative commons
Dimensione
453.38 kB
Formato
Adobe PDF
|
453.38 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
